Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMahmoud R. GaballaJCJessica ChenMHMisha Hawkins

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows varying toxicity profiles and expansion in car t-cell therapies for multiple myeloma.

Key Points

  • This research aims to evaluate the expansion dynamics and toxicity profiles of two CAR T-cell therapies for multiple myeloma.
  • Retrospective analysis of 76 RRMM patients
  • CAR-T quantification through flow cytometry
  • Statistical tests including Fisher's exact and Wilcoxon rank sum tests
  • Kaplan-Meier for time-to-event analyses
  • Median peak CAR-T level for ide-cel was 600 cells/µL; for cilta-cel it was 1281 cells/µL
  • Higher peak ALC in cilta-cel group correlated with increased grade ≥2 CRS and ICANS
  • No significant correlation between CAR-T levels and most specific toxicities
  • Both therapies have different toxicity profiles and expansion dynamics.

Cite This Study

Gaballa et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d16ahttps://doi.org/10.1182/blood-2025-5850
View Full Paper
Ask AI
Bookmark
Share